Intensity-modulated radiation therapy for gastrointestinal tumors

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 206-211

  Meyer, Jeffrey J ^b   Czito, Brian G ^a   Willett, Christopher G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSIMETRY; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GROSS TUMOR VOLUME; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PANCREAS ADENOCARCINOMA; PELVIS TUMOR; PLANNING TUMOR VOLUME; RADIATION BEAM; RECTUM CANCER; REVIEW; SKIN TOXICITY; STOMACH CANCER; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; TUMOR VOLUME; GASTROINTESTINAL TUMOR; METHODOLOGY;

GASTROINTESTINAL NEOPLASMS; HUMANS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 58149106079     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0032-9     Document Type: Review

References (46)

1. Verhey LJ: Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999, 9:78-98.
2. Zelefsky MJ, Fuks Z, Leibel SA: Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002, 12:229-237.
3. Chao KS: Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002, 12(Suppl 1):20-25.
4. Jiang SB: Radiotherapy of mobile tumors. Semin Radiat Oncol 2006, 16:239-248.
5. Gierga DP, Chen GT, Kung JH, et al.: Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys 2004, 58:1584-1595.
6. Jiang SB, Pope C, Al Jarrah KM, et al.: An experimental investigation on intra-fractional organ motion effects in lung IMRT treatments. Phys Med Biol 2003, 48:1773-1784.
7. Paulino AC, Skwarchuk M: Intensity-modulated radiation therapy in the treatment of children. Med Dosim 2002, 27:115-120.
8. Schultz RJ, Kagan AR: On the role of intensity-modulated radiation therapy in radiation oncology. Med Phys 2002, 29:1473-1482.
9. Mariette CZ, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 2007, 8:545-553.
10. Minsky BD, Pajak TF, Ginsberg RJ, et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
11. Gaspar LE, Winter K, Kocha WI, et al.: A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): Final report. Cancer 2000, 88:988-995.
12. Chandra A, Guerrero TM, Liu HH, et al.: Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005, 77:247-253.
13. Wu VW, Sham JS, Kwong DL: Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol 2004, 77:568-572.
14. Nutting CM, Bedford JL, Cosgrove VP, et al.: A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 2001, 61:157-163.
15. Fu WH, Wang LH, Zhou ZM, et al.: Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol 2004, 10:1098-1102.
16. Zhang ZX, Gu XZ, Yin WB, et al.: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys 1998, 42:929-934.
17. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
18. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
19. Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:2149-2153.
20. Knab B, Rash C, Farrey K: Intensity-modulated radiotherapy for neoadjuvant treatment of gastric cancer. Med Dosim 2006, 31:292-297.
21. Milano MT, Garofalo MC, Chmura SJ, et al.: Intensity-modulated radiation therapy in the treatment of gastric cancer: Early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol 2006, 79:497-503.
22. Ringash J, Perkins ZG, Brierley J, et al.: IMRT for adjuvant radiation in gastric cancer: A preferred plan? Int J Radiat Oncol Biol Phys 2005, 63:732-738.
23. Wieland P, Dobler B, Mai S, et al.: IMRT for postoperative treatment of gastric cancer: Covering large target volumes An the upper abdomen: a comparison of step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 2004, 59:1236-1244.
24. Lohr F, Dobler B, Mai S, et al.: Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 2003, 179:557-563.
25. Crane CH, Abbruzzese JL, Evans DB, et al.: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002, 52:1293-1302.
26. Wilkowski R, Thoma M, Schauer R, et al.: Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2003, 28:1011-1018.
27. Milano MT, Chmura SJ, Garofalo MC, et al.: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59:445-453.
28. Ben-Josef E, Shields AF, Vaishampayan U, et al.: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 59:454-459.
29. Spalding AC, Jee KW, Vineberg K, et al.: Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007, 34:521-529.
30. Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005, 15:279-283.
31. Choi BO, Jang HS, Kang KM, et al.: Fractionated stereotactic radiotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 2006, 36:212-217.
32. Marks LB, Prosnitz LR: Postoperative rTdiotherapy for lung cancer: the breast cancer story all over again? Int J Radiat Oncol Biol Phys 2000, 48:625-627.
33. Nigro ND, Vaitkevicius VK, Considine B, Jr: Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 1974, 17:354-356.
34. Mohiuddin M, Regine WF, John WJ, et al.: Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathologic complete response. Int J Radiat Oncol Biol Phys 2000, 46:883-888.
35. Overgaard M, Overgaard J, Sell A: Dose-response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. Radiother Oncol 1984, 1:217-225.
36. Constantinou EC, Daly W, Fung CY, et al.: Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997, 39:651-657.
37. Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
38. Baglan KL, Frazier RC, Dan Y, et al.: The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002, 52:176-183.
39. Tho LM, Glegg M, Paterson J, et al.: Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006, 66:505-513.
40. Gunnlaugsson A, Kjellen E, Nilsson P, et al.: Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007, 46:937-944.
41. Bartelink H, Roelofsen F, Eschwege F, et al.: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
42. Ashman JB, Zelefsky MJ, Hunt MS, et al.: Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:761-765.
43. Mundt AJ, Lujan AR, Rotmensch J, et al.: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330-1337.
44. Guerrero Urbano MT, Henrys AJ, Adams EJ, et al.: Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of small bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006, 65:907-916.
45. Milano MT, Jani AB, Farrery KJ, et al.: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63:354-361.
46. Salama JK, Mell LK, Schomas DA, et al.: Concurrent chemotherapy and intensity-modulated radiation therapy for anal cancer patients: A multicenter experience. J Clin Oncol 2007, 25:4581-4586.